Patents by Inventor Thomas Craven Baddeley
Thomas Craven Baddeley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115580Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: ApplicationFiled: December 8, 2023Publication date: April 11, 2024Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 11951110Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.Type: GrantFiled: February 2, 2022Date of Patent: April 9, 2024Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 11878021Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: GrantFiled: June 23, 2021Date of Patent: January 23, 2024Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 11344558Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.Type: GrantFiled: October 30, 2015Date of Patent: May 31, 2022Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20220152038Abstract: Described are methods of prepraing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly usefull for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.Type: ApplicationFiled: February 2, 2022Publication date: May 19, 2022Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20220098161Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: ApplicationFiled: October 12, 2021Publication date: March 31, 2022Applicant: WisTa Laboratories Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Patent number: 11180464Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: GrantFiled: January 24, 2020Date of Patent: November 23, 2021Assignee: WisTa Laboratories Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Publication number: 20210322435Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: ApplicationFiled: June 23, 2021Publication date: October 21, 2021Applicant: Wis Ta Laboratories Ltd.Inventors: Claude Michel Wischik, John Mervy David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 11045477Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: GrantFiled: November 15, 2019Date of Patent: June 29, 2021Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 10864216Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: GrantFiled: March 5, 2018Date of Patent: December 15, 2020Assignee: WisTa Laboratories, Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Publication number: 20200261465Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: ApplicationFiled: November 15, 2019Publication date: August 20, 2020Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20200246350Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: ApplicationFiled: January 24, 2020Publication date: August 6, 2020Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Patent number: 10525061Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: GrantFiled: May 23, 2018Date of Patent: January 7, 2020Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20190046537Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: ApplicationFiled: March 5, 2018Publication date: February 14, 2019Applicant: WisTa Laboratories Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Publication number: 20180263999Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: ApplicationFiled: May 23, 2018Publication date: September 20, 2018Applicant: WISTA LABORATORIES LTD.Inventors: Claude Michel WISCHIK, John Mervyn David STOREY, Colin MARSHALL, James Peter SINCLAIR, Thomas Craven BADDELEY
-
Patent number: 9980971Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: GrantFiled: June 9, 2017Date of Patent: May 29, 2018Assignee: WISTA LABORATORIES LTD.Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 9907804Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: GrantFiled: February 29, 2016Date of Patent: March 6, 2018Assignee: WISTA LABORATORIES LTD.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Publication number: 20170273986Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: ApplicationFiled: June 9, 2017Publication date: September 28, 2017Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel WISCHIK, John Mervyn David STOREY, Colin MARSHALL, James Peter SINCLAIR, Thomas Craven BADDELEY
-
Patent number: 9675621Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: GrantFiled: June 17, 2016Date of Patent: June 13, 2017Assignee: WISTA LABORATORIES LTD.Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20160296531Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.Type: ApplicationFiled: June 17, 2016Publication date: October 13, 2016Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel WISCHIK, John Mervyn David STOREY, Colin MARSHALL, James Peter SINCLAIR, Thomas Craven BADDELEY